Woodline Partners 13F: Adds $3M to BMY Stake

Woodline Partners Expands Bristol-Myers Squibb Stake

Woodline Partners grew its investment in Bristol-Myers Squibb Company NYSE:BMY during the quarter ended May 15, 2026, according to a recent Form 13F filing with the Securities and Exchange Commission. The fund lifted its holdings by buying 51,521 additional shares, bringing its total position to 1,120,638 shares. At the time of the filing, the investment was valued at approximately $65.62 million based on a cost basis of $58.76 per share. Because 13F filings are backward-looking documents that reflect positions held at the close of a previous quarter, this update may not represent the investor's current portfolio today.

How the Position Changed

Before this adjustment, Woodline Partners owned 1,069,117 shares of the drug maker. The 4.8% increase expanded the fund's stake by 51,521 shares. This move follows other recent portfolio adjustments tracked across institutional filers, adding to the fund's exposure in the healthcare sector.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb traded at $58.56 on Tuesday, sitting well within its 52-week range of $42.52 to $68.64. The company carries a market capitalization of $123.73 billion, a trailing P/E ratio of 13.34, and a forward P/E ratio of 9.14. Its 50-day moving average sits at $63.59, while its 200-day moving average rests at $59.61. The stock has a beta of 0.18, showing lower volatility than the broader market.

Recent Analyst Updates

Wall Street firms have adjusted their views on the drug maker in recent months. On October 13, 2026, Wells Fargo maintained its Equal-Weight rating while lowering its price target from $65.00 to $60.00. Cantor Fitzgerald kept a Neutral rating on October 8, 2026, cutting its target from $59.00 to $53.00. Morgan Stanley maintained an Underweight rating on October 7, 2026, raising its target slightly from $40.00 to $41.00. Earlier, on October 5, 2026, Leerink Partners downgraded the stock to Market Perform and lowered its target to $59.00 from $73.00. Piper Sandler reiterated an Overweight rating on September 16, 2026, lifting its target to $82.00 from $75.00. HSBC maintained a Hold rating on September 10, 2026, adjusting its target to $65.00 from $60.00. Argus Research upgraded the stock to a Buy on August 5, 2026, setting a $75.00 target. Finally, Citigroup maintained a Neutral rating on August 3, 2026, raising its target from $66.00 to $70.00. Overall, the stock carries a consensus recommendation of Buy with a mean price target of $65.63 across 24 analyst opinions.

Dividend Profile

Bristol-Myers Squibb offers a dividend yield of 4.16% with an annualized payout supported by a dividend payout ratio of 55.29%.

Inside the Drug Maker's Business

Headquartered in Princeton, New Jersey, Bristol-Myers Squibb discovers, develops, and distributes biopharmaceutical products worldwide. The company focuses on treatments for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Key products include the cancer therapy Opdivo, blood thinner Eliquis, and multiple myeloma drug Revlimid. The company employs roughly 32,500 people and has built a broad portfolio of specialty therapies sold to hospitals, clinics, and distributors globally.

What to Watch at Bristol-Myers Squibb Company

Investors tracking Bristol-Myers Squibb should look toward the company's next earnings report, which is scheduled for release on October 29, 2026. Future SEC filings will also show whether Woodline Partners and other institutional investors continue adjusting their stakes as market conditions evolve.